Table III. Results of Multivariate Analysis of Selected Prognostic Factors for Overall Survival, Disease-Free Survival, and Local Recurrence-Free Survival.

	Overall Survival¶		Disease-Free Survival§		Local Recurrence- Free Survival‡
Marker	HR	95% CI	HR	95% CI	HR	95% CI
P16	0.79	[0.31, 1.99]	0.96	[0.43, 2.15]	0.90	[0.20, 4.01]
CCNA1	0.96	[0.48, 1.93]	0.93	[0.49, 1.74]	0.45	[0.10, 2.03]
DCC	0.79	[0.42, 1.50]	0.97	[0.56, 1.67]	1.13	[0.45, 2.83]
TIMP3	1.77	[0.82, 3.82]	1.69	[0.92, 3.11]	2.51	[1.10, 5.68]
MGMT	0.91	[0.47, 1.75]	0.96	[0.53, 1.73]	1.62	[0.69, 3.82]
DAPK	2.19	[0.84, 5.71]	1.42	[0.59, 3.43]	1.41	[0.44, 4.53]
MINT31	2.26	[0.85, 6.05]	1.77	[0.71, 4.38]	1.66	[0.35, 7.84]
Any marker positive	0.95	[0.53, 1.69]	1.06	[0.64, 1.76]	1.63	[0.70, 3.79]

^¶For overall survival endpoint, the multivariable model included age, HPV, primary site, pathological T stage and margin status as covariates. Detailed multivariate analysis of these covariates was in Supplementary Table I.

^§For disease-free survival endpoint, the multivariable model included age, HPV, primary site and T stage as covariates. Detailed multivariate analysis of these covariates was in Supplementary Table II.

^‡For local recurrence-free survival endpoint, the multivariable model included primary site as a covariate. Detailed multivariate analysis of these covariates was in Supplementary Table III.